Skip to main content

Table 3 SNOT-22 scores (SD) in patients receiving dupilumab therapy

From: Canadian real-world study of access and clinical results using dupilumab for chronic rhinosinusitis with polyps

 

SNOT-22 Score

Baseline (n = 53)

16 weeks (n = 38)

28 Weeks (n = 36)

Full Cohort

60.56 (21.63)

23.36 (15.97)

23.47 (17.66)

 CRSwNP

57.44 (20.86)

22.28 (15.32)

21.36 (16.36)

 AERD

66.11(22.45)

25.46 (17.60)

26.78 (19.70)

  1. SNOT-22, Sinonasal Outcome Test-22; SD, Standard Deviation; CRSwNP, Chronic Rhinosinusitis with Nasal Polyps; AERD, Aspirin Exacerbated Respiratory Disease
Back to article page

Journal of Otolaryngology - Head & Neck Surgery

ISSN: 1916-0216

Contact us